Antibioticoterapia inicial apropiada | 06 AGO 12

Mortalidad hospitalaria en pacientes con shock séptico

En los pacientes con shock séptico que recibieron antibioticoterapia apropiada, los determinantes más importantes de la evolución fueron la gravedad de la enfermedad y las enfermedades asociadas.
1
16
Autor/a: Dres. Labelle A, Juang P, Reichley R, Micek S, Crit Care Med 2012:40: 2016-2021
INDICE:  1. Artículo: | 2. Referencias
Referencias

Referencias

1. Kollef MH: Broad-spectrum antimicrobials and the treatment of serious bacterial infections: Getting it right up front. Clin Infect Dis 2008; 47(Suppl 1):S3–13.
2. Dhainaut JF, Laterre PF, LaRosa SP, et al: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results. Crit Care Med 2003; 31:2291–2301.
3. Dupont H, Mentec H, Sollet JP, et al: Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355–362.
4. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:2742–2751.
5. Harbarth S, Garbino J, Pugin J, et al: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529–535.
6. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146–155.
7. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–474.
8. Micek ST, Lloyd AE, Ritchie DJ, et al: Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306–1311.
9. Shorr AF, Micek ST, Welch EC, et al: Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 2011; 39:46–51.
10. Ferrer R, Artigas A, Suarez D, et al: Edusepsis Study Group: Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180:861–866.
11. Arias CA, Murray BE: Antibiotic-resistant bugs in the 21st century–a clinical super-challenge. N Engl J Med 2009; 360:439–443.
12. Boucher HW, Talbot GH, Bradley JS, et al: Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1–12.
13. Dellinger RP, Levy MM, Carlet JM, et al: International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and shock séptico: 2008. Crit Care Med 2008; 36:296–327.
14. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818–829.
15. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303–1310.
16. Magiorakos AP, Srinivasan A, Carey RB, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–281.
17. Micek ST, Roubinian N, Heuring T, et al: Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 2006; 34:2707–2713.
18. Thiel SW, Asghar MF, Micek ST, et al: Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit Care Med 2009; 37:819–824.
19. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania, 2002.
20. Clinical Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. M100-S17. Clinical Laboratory Standards Institute, Wayne, Pennsylvania, 2007.
21. Zahar JR, Timsit JF, Garrouste-Orgeas M, et al: Outcomes in severe sepsis and patients with septic shock: Pathogen species and infection sites are not associated with mortality. Crit Care Med 2011; 39:1886–1895.
22. Puskarich MA, Trzeciak S, Shapiro NI, et al: Emergency Medicine Shock Research Network (EMSHOCKNET): Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 2011; 39:2066–2071.
23. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589–1596.
24. Joo EJ, Kang CI, Ha YE, et al: Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: A stratified analysis according to sites of infection. Infection 2011; 39: 309–318.
25. Le Berre R, Nguyen S, Nowak E, et al: Pyopneumagen Group: Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia. Crit Care Med 2011; 39:2113–2120.
26. Hauser AR, Cobb E, Bodi M, et al: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30:521–528
27. Deleo FR, Otto M, Kreiswirth BN, et al: Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010; 375: 1557–1568.
28. Cohen J: A role for the micro-organism in the outcome from infection? A principle challenged. Crit Care Med 2011; 39:2001–2002.
29. Holmes NE, Turnidge JD, Munckhof WJ, et al: Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340–347.
30. Rodriguez A, Lisboa T, Blot S, et al: Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators: Mortality in ICU patients with bacterial community-acquired pneumonia: When antibiotics are not enough. Intensive Care Med 2009; 35:430–438.
31. U.S. Food and Drug Administration: Xigris [drotrecogin alfa (activated)]: Market Withdrawal - Failure to Show Survival Benefit. Available at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm277143.htm . Accessed October 28, 2011. 

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2020